USA - NASDAQ:TEM - US88023B1035 - Common Stock
The current stock price of TEM is 71.2 USD. In the past month the price decreased by -20.37%. In the past year, price increased by 36.56%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.25 | 222.01B | ||
| DHR | DANAHER CORP | 28.49 | 157.27B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 162.78 | 49.39B | ||
| A | AGILENT TECHNOLOGIES INC | 27.96 | 43.19B | ||
| IQV | IQVIA HOLDINGS INC | 19.05 | 37.66B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.06 | 30.22B | ||
| WAT | WATERS CORP | 30.66 | 23.18B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.61 | 19.63B | ||
| ILMN | ILLUMINA INC | 28.18 | 18.88B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.32 | 17.00B | ||
| RVTY | REVVITY INC | 19.66 | 10.93B | ||
| TECH | BIO-TECHNE CORP | 31.6 | 9.50B |
Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. The company is headquartered in Chicago, Illinois and currently employs 2,400 full-time employees. The company went IPO on 2025-05-30. The company offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. The company provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
TEMPUS AI INC
600 West Chicago Avenue, Suite 510
Chicago ILLINOIS US
Employees: 2400
Phone: 18335144187
Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. The company is headquartered in Chicago, Illinois and currently employs 2,400 full-time employees. The company went IPO on 2025-05-30. The company offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. The company provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
The current stock price of TEM is 71.2 USD. The price decreased by -0.5% in the last trading session.
TEM does not pay a dividend.
TEM has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
TEM stock is listed on the Nasdaq exchange.
TEMPUS AI INC (TEM) operates in the Health Care sector and the Life Sciences Tools & Services industry.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TEM.
ChartMill assigns a technical rating of 1 / 10 to TEM. When comparing the yearly performance of all stocks, TEM is one of the better performing stocks in the market, outperforming 79.73% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to TEM. The financial health of TEM is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months TEM reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS increased by 85.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.94% | ||
| ROE | -40.15% | ||
| Debt/Equity | 2.45 |
19 analysts have analysed TEM and the average price target is 87.18 USD. This implies a price increase of 22.45% is expected in the next year compared to the current price of 71.2.
For the next year, analysts expect an EPS growth of 73.5% and a revenue growth 80.87% for TEM